Reports in pharmacological treatments in geriatric psychiatry: Is there anything new or just adding to old evidence?

Current Opinion in Psychiatry

Volumn 21, Issue 6, 2008, Pages 562-567

  Laks, Jerson ^a,c   Engelhardt, Eliasz ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

Dementia; Depression; Elderly; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; GALANTAMINE; GUANFACINE; IDAZOXAN; MEMANTINE; METHYLPHENIDATE; NOOTROPIC AGENT; OLANZAPINE; PAROXETINE; PIRACETAM; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR;

AGRANULOCYTOSIS; ALZHEIMER DISEASE; APATHY; BRAIN CIRCULATION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DELUSION; DEMENTIA; DEPRESSION; DRUG EFFICACY; ELDERLY CARE; FRONTOTEMPORAL DEMENTIA; GERONTOPSYCHIATRY; HALLUCINATION; HUMAN; LEWY BODY; NEUROPATHOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG THERAPY; EVIDENCE-BASED MEDICINE; GERIATRIC PSYCHIATRY; HUMANS; INDANS; LEWY BODY DISEASE; PARKINSON DISEASE; PIPERIDINES;

EID: 56249083215     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32830ef725     Document Type: Review

References (41)

1. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev 2007; 6:521-532. This paper is an excellent review of the difficulties and possible strategies to achieve disease modifying and curable treatments for illnesses, which affect the CNS.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
3. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Int Med 2008; 148:379-397. This study provides a systematic review of high quality studies with the two first line classes of drugs. The conclusions are confirmations of the effectiveness and limitations of the available treatments.
4. Feldman H, Gauthier S, Hecker H, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57:613-620.
5. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69:459-469. This study confirms a previous double-blind placebo-controlled study with a cholinesterase inhibitor in severe Alzheimer's disease. Donepezil demonstrated greater benefit on cognition and global function as compared with placebo in patients with severe Alzheimer's disease.
6. Mercier F, Lefèvre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007; 23:3199-3204. The patch delivery provides the same efficacy and better tolerability profile as compared with the rivastigmine capsule presentation.
7. Erkinjuntii T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283-1290.
8. Erkinjuntti T, Gauthier S, Bullock R, et al. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol 2008 [Epub ahead of print]. This study is a further analysis of a previous study of Alzheimer's disease with cerebrovascular disease patients now focusing on the patients who were responders.
9. Reisberg B, Doody R, Stöffler A, et al., Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333-1341.
10. Reisberg B, Doody R, Stöffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63:49-54.
11. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21:136-143. This study did not find the same results published previously by Reisberg et al. [9,10].
12. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14:704-715.
13. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13:97-107. This study confirmed Peskind et al.'s [12] results in weeks 12 and 18, but not in week 24. It agrees with van Dyck et al. [11*].
14. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5:83-89. In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate. Alzheimer's disease on stable cholinesterase inhibitor regimens.
15. McShane R, Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006 Apr 19;(2):CD003154.
16. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuro-imaging studies. Alzheimer Dis Assoc Disord 2007; 21:S79-S87. This is a review of the recent findings that may facilitate the discovery of disease modifying pharmacological treatments for FTD.
17. 1a antagonists might be useful.
18. Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sc. 2007; 34 (Suppl 1): S118-S124. This is another review on the difficulties of achieving safe and effective treatment in FTD.
19. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontolemporal dementia. Am J Geriatr Psychiatry 2007; 15:84-87. This study confirms the present view that cholinesterase inhibitors are not indicated for FTD treatment.
20. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004; 21:931-937.
21. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008; 25:178-185. Galantamine was not effective in the frontal variant, but there was a trend of efficacy in the progressive aphasia subgroup.
22. Diehl-Schmid J, Forstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia, Int J Geriatr Psychiatry. 2008 [Epub ahead of print] This study shows that there is no additional response with memantine in FTD patients.
23. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
24. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-2518.
25. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76:934-939.
26. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007; 23:401-405. This study reports a good profile of galantamine in Lewy body dementia (LBD), as already seen with the two other cholinesterase inhibitors.
27. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21:1899-1907.
28. Rozzini L, Chilovi BV, Bertoletti E, et al. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. Am J Alzheimers Dis Other Demen 2007; 22:42-47. This is a well-designed case control-study showing efficacy of rivastigmine in LBD, confirming previous reports.
29. Alisky JM. Memantine-induced decompensation in a patient with lewy body dementia. Ann Acad Med Singapore 2007; 36:707. Some patients may show more agitation and confusion with memantine in LBD.
30. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68:812-819. This is a comprehensive update on the diseases with Lewy body pathology.
31. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy Bodies. Am J Psychiatry 2007; 164:1491-1498. Based on open-label studies and clinical experience, quetiapine is the current first-line antipsychotic treatment.
32. Teodorczuk A, O'Brien JT, Firbank MJ, et al. White matter changes and late-life depressive symptoms. BMJ 2007; 191:212-217. Depressive psychopathology and symptoms may be related to some microangiopathic lesions in the brain, and may further define response and remission.
33. Baldwin RC. Is vascular depression a distinct subtype of depressive disorder? A review of the causal evidence, Int J Geriatr Psychiatry 2005; 20:1-11.
34. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry 2008; 165:238-244. This study shows that treatment resistance to antidepressant medication may be related to white matter disease in the brain.
35. Kozel F, Trivedi M, Wisniewski S, et al. Treatment outcomes for older depressed patients with early versus late onset of first depressive episode. A Sequenced Treatment Alternatives to Relieve Depression Trial (STAR*D) report. Am J of Geriatr Psychiatry 2008; 16:58-64. STAR* D trials have been yielding sound data on clinically important questions. This is one of the studies with the elderly that shows the response to antidepressants of late onset versus early onset first depressive episode.
36. Zisook S, Lesser I, Stewart JW, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 2007; 164:1539-1546. As the previous referenced publication, this is another study with further results on the issue of early versus late onset of depression.
37. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. Am J Psychiatiy 2007; 164: 900-909. Improvement on cognition due to amelioration of depression may be important for remission and for resuming normal activities of daily living. This study is a well designed trial with duloxetine in the elderly.
38. Kiosses DN, Alexopoulos GS. IADL functions, cognitive deficits, and severity of depression. A preliminary study. Am J Geriatr Psychiatry 2005; 13:244-249.
39. Dombrovski AY, Lenze EJ, Dew MA, et al. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. JAGS 2007; 55:1325-1332. Remission and response to treatment is meaningful depending on the final outcome on quality of life. This study shows a daily issue that has been rarely studied in depressed elderly patients.
40. Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 2002; 10:129-141.
41. Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a meta-analysis. Can J Psychiatry 2007; 52:248-255. This study provides clinically relevant information for the treatment of depression in Alzheimer's disease, showing comparable efficacy and safety profiles of antidepressants in dementia to those in elderly patients without cognitive impairment.